Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 34,264	$ 15,552
General and administrative	19,239	14,807
Acquired in-process research and development		164,617
Total operating expenses	53,503	194,976
Loss from operations	(53,503)	(194,976)
Other income (expense):
Interest and investment income	1,724	122
Other expense, net	(55)	(58)
Total other income, net	1,669	64
Net loss	(51,834)	(194,912)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs		(24,437)
Net loss attributable to common shareholders	$ (51,834)	$ (219,349)
Net loss per share attributable to common shareholders - basic	$ (3.55)	$ (24.58)
Net loss per share attributable to common shareholders - diluted	$ (3.55)	$ (24.58)
Weighted-average common shares outstanding used in net loss per share - basic	14,620,618	8,925,173
Weighted-average common shares outstanding used in net loss per share - diluted	14,620,618	8,925,173